H. C. Rümke - Concepedia

Author

H. C. Rümke

National Institute for Public Health and the Environment

Also Known As

H C RUMKE, H C Rumke, H C Rümke, H RUMKE, H Rumke, H Rümke, H. C Rumke, H. C. Rumke, H. C. Rümke, H. C. R�mke

Publications

3.1K

Citations

H-Index

Concepts

All Affiliations

National Institute for Public Health and the Environment Erasmus University Rotterdam Rotterdam University of Applied Sciences Erasmus MC Ghent University Hospital

About

H. C. Rümke is an author at National Institute for Public Health and the Environment specializing in medicine, vaccination, and immunology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	20	25	2K
2	Public Health	6	6	504
3	Cell Biology	2	2	34
4	Social Sciences	1	1	81
5	Allergy	1	1	29

H. C. Rümke

Publications

2.3K

Citations

H-Index

Page 1

	Year	Citations
Immunization of Early Adolescent Females with Human Papillomavirus Type 16 and 18 L1 Virus-Like Particle Vaccine Containing AS04 Adjuvant Court Pedersen, Tiina Petäjä, Gitte Strauss, Journal of Adolescent Health VaccinationEarly Adolescent FemalesVaccine DevelopmentHuman Papillomavirus VaccinesImmunology	2007	240
Reemergence of Pertussis in the Highly Vaccinated Population of The Netherlands: Observations on Surveillance Data Hester E. de Melker, J. F. P. Schellekens, S E Neppelenbroek, Emerging infectious diseases VaccinationInfectious Disease EpidemiologyPertussis ReportingVaccine DevelopmentVaccine Surveillance	2000	226
Immunogenicity and reactogenicity in UK infants of a novel meningococcal vesicle vaccine containing multiple class 1 (PorA) outer membrane proteins Keith Cartwright, Rhonwen Morris, H. C. Rümke, Vaccine VaccinationUk InfantsVaccine DevelopmentMedicineVaccine Target	1999	177
Phase I clinical trial with a hexavalent PorA containing meningococcal outer membrane vesicle vaccine C C Peeters, H. C. Rümke, L.C. Sundermann, Vaccine VaccinationVaccine DevelopmentImmunologyMicrobiologyInfection Control	1996	158
Pertussis in the Netherlands: an Outbreak Despite High Levels of Immunization with Whole-Cell Vaccine Hester E. de Melker, M.A.E. Conyn-van Spaendonck, H. C. Rümke, Emerging infectious diseases VaccinationVaccine SafetyVector-borne PathogenVaccine DevelopmentTrue Outbreak	1997	156
The epidemiology of varicella and herpes zoster in The Netherlands: Implications for varicella zoster virus vaccination Hester E. de Melker, Guy A. M. Berbers, Susan Hahné, Vaccine VaccinationVaccine SafetyVirus EpidemiologyHerpes ZosterVirology	2006	139
Immunogenicity and safety of a hexavalent meningococcal outer-membrane-vesicle vaccine in children of 2–3 and 7–8 years of age Ester D. de Kleijn, Ronald de Groot, Jerry Labadie, Vaccine VaccinologyVaccinationVaccine DevelopmentImmunologyInfection Control	2000	138
Comparative immunogenicity of a PreS/S hepatitis B vaccine in non- and low responders to conventional vaccine Pamela Rendi‐Wagner, Daniel Shouval, Blaise Genton, Vaccine VaccinationVaccinologyConventional VaccineLow RespondersViral Hepatitis	2006	136
Safety and reactogenicity profile of an adjuvanted H5N1 pandemic candidate vaccine in adults within a phase III safety trial H. C. Rümke, José-María Bayas, José-Ramón de Juanes, Vaccine VaccinationVaccine SafetyCross-protectionVaccine DevelopmentImmunology	2008	94
A randomized, double-blind trial to evaluate immunogenicity and safety of 13-valent pneumococcal conjugate vaccine given concomitantly with trivalent influenza vaccine in adults aged ≥65 years Tino F. Schwarz, Johan Flamaing, H. C. Rümke, Vaccine ImmunologyImmunodominanceFlu VaccinationInfluenza VaccinesPreventive Medicine	2011	93

Page 1